Form 4: Quest Diagnostics Executive Acquires Shares Through Dividend Reinvestment

Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics, acquired 25 shares of common stock through a dividend reinvestment plan.

Summary

• On April 21, 2025, Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics, acquired 25 shares of common stock.
• The shares were acquired through a dividend reinvestment plan at a price of $164.421 per share.
• Following the transaction, Delaney directly owns 9,246 shares of Quest Diagnostics common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects a routine transaction. Executive increasing stake is mildly positive.

Positives

• The acquisition of shares by a company executive can be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

There are no specific forward-looking statements in this document.

Industry Context

This is a routine transaction related to executive compensation and dividend reinvestment, common in publicly traded companies.

Comparison to Industry Standards

• Dividend reinvestment plans are a common method for employees and executives to increase their ownership in a company.
• Executive stock ownership is generally viewed positively by investors as it aligns management's interests with those of shareholders.
• Comparing Delaney's holdings to those of other executives at Quest Diagnostics and similar companies would provide further context.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals confidence from a company executive.

Key Dates

Keywords

Quest Diagnostics, Mark E. Delaney, dividend reinvestment plan, stock acquisition, Form 4, DGX, executive, ownership